Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
6th Man Ventures: Purchased $1.5 million worth of META on the open market at an average price of $6.35

6th Man Ventures: Purchased $1.5 million worth of META on the open market at an average price of $6.35

ChaincatcherChaincatcher2025/10/20 00:22
Show original

ChainCatcher news, @CompoCapital, Head of Liquidity at venture capital firm 6th Man Ventures, announced that 6th Man Ventures has acquired $1.5 million worth of MetaDAO (META) at a price of $6.35. Possibly influenced by this news, META is now trading at $8.34, with a 24-hour increase of 32.51%.

The announcement stated that MetaDAO's robust ICO platform gained strong traction in its early stages—attracting over $200 million in funding for founders, while granting liquidity investors rights and fundamentally aligning incentives between both parties—representing a significant step forward in the evolution of on-chain capital formation. Previously, the MetaDAO community passed a proposal to "sell up to 2 million META at market price or at a premium."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.

U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).

智通财经2026/09/21 07:11

Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential

According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.

智通财经2026/09/21 07:11

Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.

TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).

智通财经2026/09/21 07:11